-

Dexcom to Host Investor Day on December 9, 2020

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business strategy, innovation efforts and long-term financial outlook.

Dexcom will host a live webcast of the event with no pre-registration required, enabling access for all interested stakeholders. The webcast can be accessed at dexcom2020investorday.com, or by navigating to the Dexcom Investor Relations website (https://investors.dexcom.com/) on the Events and Presentations page. A replay of the event will be available shortly after its conclusion.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom to Host Investor Day on December 9, 2020
Release Versions
English

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

More News From DexCom, Inc.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo...

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer...

Dexcom Appoints Glenn Boehnlein to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology...
Back to Newsroom